Table 4.
Differential expression of the miRNA level in the serum from controls and OA patients, analyzed by next-generation sequencing
| Names | Log2 fold change | p value | FDR adjusted p value | Healthy average TPM | OA average TPM |
|---|---|---|---|---|---|
| hsa-miR-139-5p | 0.73 | 0.0001 | 0.0434 | 90.1 | 143.3 |
| hsa-miR-1299 | − 3.38 | 0.0002 | 0.0434 | 12 | 0.8 |
| hsa-miR-200a-3p | − 1.88 | 0.0003 | 0.0473 | 77.2 | 29.4 |
| hsa-miR-129-5p | 0.81 | 0.0022 | 0.1640 | 3.6 | 6.5 |
| hsa-miR-429 | − 1.43 | 0.0023 | 0.1640 | 5.5 | 2.5 |
| hsa-miR-9-5p | 0.83 | 0.0045 | 0.2410 | 3.2 | 6.1 |
| hsa-miR-375 | − 0.93 | 0.0065 | 0.2795 | 737 | 411.3 |
| hsa-miR-139-3p | 0.61 | 0.0072 | 0.2820 | 48.8 | 69.7 |
| hsa-miR-200b-3p | − 1.18 | 0.0089 | 0.3193 | 28 | 15.7 |
| hsa-miR-150-5p | 0.72 | 0.0164 | 0.4619 | 173.6 | 252.6 |
| hsa-miR-192-5p | − 1.03 | 0.0171 | 0.4619 | 1837.8 | 1161.9 |
| hsa-miR-155-5p | 0.52 | 0.0193 | 0.4907 | 64.9 | 87.5 |
| hsa-miR-15b-3p | − 0.73 | 0.0247 | 0.5867 | 43.8 | 24.3 |
| hsa-miR-1228-5p | 0.78 | 0.0295 | 0.5918 | 4.9 | 8.7 |
| hsa-miR-126-3p | 0.38 | 0.0304 | 0.5918 | 3243.9 | 3976.7 |
| hsa-miR-206 | 1.10 | 0.0338 | 0.6011 | 51.3 | 95.9 |
| hsa-miR-199b-5p | − 0.57 | 0.0373 | 0.6011 | 29.9 | 18.6 |
| hsa-miR-1246 | 0.67 | 0.0375 | 0.6011 | 29.9 | 46.9 |
| hsa-miR-10b-5p | 0.46 | 0.0428 | 0.6390 | 3848.4 | 5039.8 |
| hsa-miR-642a-3p | 0.69 | 0.0444 | 0.6405 | 4.5 | 7.2 |
| hsa-miR-186-5p | − 0.45 | 0.0473 | 0.6405 | 777.7 | 534 |
| hsa-miR-10a-5p | 0.45 | 0.0493 | 0.6469 | 2613.1 | 3361.1 |
When we compared the OA vs healthy groups, 22 miRNAs showed differential expression (p < 0.05) between controls and OA patients. After Benjamini-Hochberg false discovery rate (FDR) correction, hsa-miR-139-5p, hsa-miR-1299, and hsa-miR-200a-3p remained significantly different between OA patients and controls (p < 0.05, FDR at 5%)